Key points are not available for this paper at this time.
Summary Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax‐based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA‐CLL13), specifically focus on this topic while real‐word evidence is missing. In our real‐life retrospective study conducted on 61 patients with CLL and treated with venetoclax‐based regimens in any therapeutic line, we documented a remarkable lower progression‐free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.
Serafin et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: